Article

Interleukin-4 polymorphisms and response to combination therapy in Egyptian chronic hepatitis C patients.

Department of Medical Biochemistry, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Cellular Immunology (impact factor: 1.97). 04/2012; 276(1-2):110-3. DOI:10.1016/j.cellimm.2012.04.009 pp.110-3
Source: PubMed

ABSTRACT In hepatitis C infection, the production of inappropriate cytokines levels may contribute to viral persistence and may affect the response to antiviral therapy. We investigate the effect of IL4 C-590T and C-33T polymorphisms on the response to combination therapy with interferon and ribavirin in chronic HCV patients. These single nucleotide polymorphisms were determined by PCR-RFLP in 235 responder and 210 non-responder to combination therapy. The IL4-590 T/T and -33 T/T genotypes were associated with resistance to the therapy (p<0.001, p=0.001 respectively). Haplotypes T(-590) T(-33) and T(-590) C(-33) were associated with a higher risk in non-responder patients than the responders (p<0.001 for each) while frequency of haplotype C(-590) C(-33) (with all wild alleles) was significantly higher in responders as compared to non-responders (p<0.001). These results suggest that inheritance of the IL4 polymorphisms may be associated with resistance to combined antiviral therapy in Egyptian HCV patients.

0 0
 · 
0 Bookmarks
 · 
33 Views

Keywords

-33 T/T genotypes
 
235 responder
 
C-33T polymorphisms
 
chronic HCV patients
 
combination therapy
 
Egyptian HCV patients
 
hepatitis C infection
 
higher risk
 
inappropriate cytokines levels
 
interferon
 
non-responder patients
 
non-responders
 
PCR-RFLP
 
responders
 
single nucleotide polymorphisms
 
viral persistence